Skip to main content
Erschienen in: Pediatric Drugs 3/2009

01.06.2009 | Commentary

Multimodal Treatments versus Pharmacotherapy Alone in Children with Psychiatric Disorders

Implications of Access, Effectiveness, and Contextual Treatment

verfasst von: Dr Gloria Reeves, Bruno Anthony

Erschienen in: Pediatric Drugs | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Practice guidelines for the treatment of youth with mental health problems tend to endorse integrating psychopharmacologic treatment with psychosocial interventions, such as psychotherapy and parent skills training. However, poor access to pediatric mental health specialists and inadequate training of primary care physicians in psychosocial interventions make it difficult for families to receive this standard of care. Large pediatric randomized, multicenter trials, including the Multimodal Treatment Study of ADHD (attention deficit hyperactivity disorder) [MTA] and the Treatment for Adolescents with Depression Study (TADS), have begun to identify specific advantages of multimodal treatment compared with psychopharmacology alone. Advantages of combined treatment include improvement of both symptoms and family functioning. More research is needed to determine effective and appropriate multimodal interventions for complex and severe pediatric mental illness. Advantages of multimodal treatment must be balanced with the treatment burden on the family system.
Literatur
1.
Zurück zum Zitat Report of the Working Group on Psychotropic Medications for Children and Adolescents: psychopharmacological, psychosocial, and combined interventions for childhood disorders: evidence base, contextual factors, and future directions [online]. Available from URL: http://www.apa.org/pi/cyf/childmeds.pdf [Accessed 2008 Oct 15] Report of the Working Group on Psychotropic Medications for Children and Adolescents: psychopharmacological, psychosocial, and combined interventions for childhood disorders: evidence base, contextual factors, and future directions [online]. Available from URL: http://​www.​apa.​org/​pi/​cyf/​childmeds.​pdf [Accessed 2008 Oct 15]
2.
Zurück zum Zitat Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry 2007 Feb; 46(2): 267–83 Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry 2007 Feb; 46(2): 267–83
3.
Zurück zum Zitat Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2007 Jan; 46(1): 107–25 Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2007 Jan; 46(1): 107–25
4.
Zurück zum Zitat Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 2007 Nov; 46(11): 1503–26 Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 2007 Nov; 46(11): 1503–26
5.
Zurück zum Zitat Ma J, Lee KV, Stafford RS. Depression treatment during outpatient visits by U.S. children and adolescents. J Adolesc Health 2005 Dec; 37(6): 434–42PubMedCrossRef Ma J, Lee KV, Stafford RS. Depression treatment during outpatient visits by U.S. children and adolescents. J Adolesc Health 2005 Dec; 37(6): 434–42PubMedCrossRef
6.
Zurück zum Zitat Leigh H, Stewart D, Mallios R. Mental health and psychiatry training in primary care residency programs: part II. What skills and diagnoses are taught, how adequate, and what affects training directors’ satisfaction? Gen Hosp Psychiatry 2006 May–Jun; 28(3): 195–204PubMedCrossRef Leigh H, Stewart D, Mallios R. Mental health and psychiatry training in primary care residency programs: part II. What skills and diagnoses are taught, how adequate, and what affects training directors’ satisfaction? Gen Hosp Psychiatry 2006 May–Jun; 28(3): 195–204PubMedCrossRef
7.
Zurück zum Zitat Richardson LP, Lewis CW, Casey-Goldstein M, et al. Pediatric primary care providers and adolescent depression: a qualitative study of barriers to treatment and the effect of the black box warning. J Adolesc Health 2007 May; 40(5): 433–9PubMedCrossRef Richardson LP, Lewis CW, Casey-Goldstein M, et al. Pediatric primary care providers and adolescent depression: a qualitative study of barriers to treatment and the effect of the black box warning. J Adolesc Health 2007 May; 40(5): 433–9PubMedCrossRef
8.
Zurück zum Zitat Kim WJ. Child and adolescent psychiatry workforce: a critical shortage and national challenge. Acad Psychiatry 2003 Winter; 27(4): 277–82PubMedCrossRef Kim WJ. Child and adolescent psychiatry workforce: a critical shortage and national challenge. Acad Psychiatry 2003 Winter; 27(4): 277–82PubMedCrossRef
9.
Zurück zum Zitat Foster EM, Jensen PS, Schlander M, et al. Treatment for ADHD: is more complex treatment cost-effective for more complex cases? Health Serv Res 2007 Feb; 42: 165–82PubMedCrossRef Foster EM, Jensen PS, Schlander M, et al. Treatment for ADHD: is more complex treatment cost-effective for more complex cases? Health Serv Res 2007 Feb; 42: 165–82PubMedCrossRef
10.
Zurück zum Zitat Vitiello B. An update on publicly funded multisite trials in pediatric psychopharmacology. Child Adolesc Psychiatric Clin N Am 2006; 15: 1–12CrossRef Vitiello B. An update on publicly funded multisite trials in pediatric psychopharmacology. Child Adolesc Psychiatric Clin N Am 2006; 15: 1–12CrossRef
11.
Zurück zum Zitat MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention deficit/hyperactivity disorder (ADHD). Arch Gen Psychiatry 1999a Dec; 56(12): 1073–86CrossRef MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention deficit/hyperactivity disorder (ADHD). Arch Gen Psychiatry 1999a Dec; 56(12): 1073–86CrossRef
12.
Zurück zum Zitat March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA 2004 Aug; 292(7): 807–20PubMedCrossRef March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA 2004 Aug; 292(7): 807–20PubMedCrossRef
13.
Zurück zum Zitat Greenhill LL, Abikoff HB, Arnold LE, et al. Medication treatment strategies in the MTA study: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry 1996 Oct; 35(10): 1304–13PubMedCrossRef Greenhill LL, Abikoff HB, Arnold LE, et al. Medication treatment strategies in the MTA study: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry 1996 Oct; 35(10): 1304–13PubMedCrossRef
14.
Zurück zum Zitat Pelham WE, Hoza B. Intensive treatment: a summer treatment program for children with ADHD. In: Hibbs ED, Jensen PS, editors. Psychosocial treatments for empirically-based strategies for clinical practice. New York: American Psychological Association, 1996: 311–40CrossRef Pelham WE, Hoza B. Intensive treatment: a summer treatment program for children with ADHD. In: Hibbs ED, Jensen PS, editors. Psychosocial treatments for empirically-based strategies for clinical practice. New York: American Psychological Association, 1996: 311–40CrossRef
15.
Zurück zum Zitat Conners CK, Epstein JN, March JS, et al. Multimodal treatment of ADHD in the MTA: an alternative outcome analysis. J Am Acad Child Adolesc Psychiatry 2001 Feb; 40(2): 159–67PubMedCrossRef Conners CK, Epstein JN, March JS, et al. Multimodal treatment of ADHD in the MTA: an alternative outcome analysis. J Am Acad Child Adolesc Psychiatry 2001 Feb; 40(2): 159–67PubMedCrossRef
16.
Zurück zum Zitat Wells KC, Chi TC, Hinshaw SP, et al. Treatment-related changes in objectively measured parenting behaviors in the multimodal treatment study of children with attention-deficit/hyperactivity disorder. J Consult Clin Psychol 2006 Aug; 74(4): 649–57PubMedCrossRef Wells KC, Chi TC, Hinshaw SP, et al. Treatment-related changes in objectively measured parenting behaviors in the multimodal treatment study of children with attention-deficit/hyperactivity disorder. J Consult Clin Psychol 2006 Aug; 74(4): 649–57PubMedCrossRef
17.
Zurück zum Zitat Patterson GR, Reid JB, Dishion TJ. Antisocial boys: Vol. 4. A social interactional approach. Eugene (OR): Castalia, 1992 Patterson GR, Reid JB, Dishion TJ. Antisocial boys: Vol. 4. A social interactional approach. Eugene (OR): Castalia, 1992
18.
Zurück zum Zitat Pierce EW, Ewing LJ, Campbell SB. Diagnostic status and symptomatic behavior of hard-to-manage preschool children in middle childhood and early adolescence. J Clin Child Psychol 1999 Mar; 28(1): 44–57PubMedCrossRef Pierce EW, Ewing LJ, Campbell SB. Diagnostic status and symptomatic behavior of hard-to-manage preschool children in middle childhood and early adolescence. J Clin Child Psychol 1999 Mar; 28(1): 44–57PubMedCrossRef
19.
Zurück zum Zitat The MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics 2004; 113(4): 754–61CrossRef The MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics 2004; 113(4): 754–61CrossRef
20.
Zurück zum Zitat The MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 2004; 113(4): 762–9CrossRef The MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 2004; 113(4): 762–9CrossRef
21.
Zurück zum Zitat Jensen PS, Arnold LE, Swanson JM, et al. 3-year follow-up of the NIMH MTA Study. J Am Acad Child Adolesc Psychiatry 2007 Aug; 46(8): 988–1002CrossRef Jensen PS, Arnold LE, Swanson JM, et al. 3-year follow-up of the NIMH MTA Study. J Am Acad Child Adolesc Psychiatry 2007 Aug; 46(8): 988–1002CrossRef
22.
Zurück zum Zitat Molina BS, Flory K, Hinshaw SP, et al. Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry 2007 Aug; 46(8): 1028–40PubMedCrossRef Molina BS, Flory K, Hinshaw SP, et al. Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry 2007 Aug; 46(8): 1028–40PubMedCrossRef
23.
Zurück zum Zitat Swanson JM, Hinshaw SP, Arnold LE, et al. Secondary evaluations of MTA 36-month outcomes: propensity score and growth mixture model analyses. J Am Acad Child Adolesc Psychiatry 2007 Aug; 46(8): 1003–14PubMedCrossRef Swanson JM, Hinshaw SP, Arnold LE, et al. Secondary evaluations of MTA 36-month outcomes: propensity score and growth mixture model analyses. J Am Acad Child Adolesc Psychiatry 2007 Aug; 46(8): 1003–14PubMedCrossRef
24.
Zurück zum Zitat The Treatment for Adolescents with Depression Study Team. Treatment for Adolescents with Depression Study (TADS): rationale, design, and methods. J Am Acad Child Adolesc Psychiatry 2003 May; 42(5): 531–42CrossRef The Treatment for Adolescents with Depression Study Team. Treatment for Adolescents with Depression Study (TADS): rationale, design, and methods. J Am Acad Child Adolesc Psychiatry 2003 May; 42(5): 531–42CrossRef
25.
Zurück zum Zitat March J, Silva S, Vitiello B, et al. The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks. J Am Acad Child Adolesc Psychiatry 2006 Dec; 45(12): 1393–403PubMedCrossRef March J, Silva S, Vitiello B, et al. The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks. J Am Acad Child Adolesc Psychiatry 2006 Dec; 45(12): 1393–403PubMedCrossRef
26.
Zurück zum Zitat Kennard B, Silva S, Vitiello B, et al. Remission and residual symptoms after short-term treatment in the treatment of adolescents with depression study. J Am Acad Child Adolesc Psychiatry 2006; 45(12): 1404–11PubMedCrossRef Kennard B, Silva S, Vitiello B, et al. Remission and residual symptoms after short-term treatment in the treatment of adolescents with depression study. J Am Acad Child Adolesc Psychiatry 2006; 45(12): 1404–11PubMedCrossRef
27.
Zurück zum Zitat Hollon SD, Garber J, Shelton RC. Treatment ofdepression in adolescents with cognitive behavior therapy and medications: a commentary on the TADS project. Cogn Behav Pract 2005; 12(2): 149–55CrossRef Hollon SD, Garber J, Shelton RC. Treatment ofdepression in adolescents with cognitive behavior therapy and medications: a commentary on the TADS project. Cogn Behav Pract 2005; 12(2): 149–55CrossRef
28.
Zurück zum Zitat March JS, Silva S, Petrycki S, et al. The Treatment for Adolescents with Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry 2007 Oct; 64(10): 1132–44PubMedCrossRef March JS, Silva S, Petrycki S, et al. The Treatment for Adolescents with Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry 2007 Oct; 64(10): 1132–44PubMedCrossRef
29.
Zurück zum Zitat Hack S, Chow B. Pediatric psychotropic medication compliance: a literature review and research-based suggestions for improving treatment compliance. J Child Adolesc Psychopharmacol 2001 Spring; 11(1): 59–67PubMedCrossRef Hack S, Chow B. Pediatric psychotropic medication compliance: a literature review and research-based suggestions for improving treatment compliance. J Child Adolesc Psychopharmacol 2001 Spring; 11(1): 59–67PubMedCrossRef
Metadaten
Titel
Multimodal Treatments versus Pharmacotherapy Alone in Children with Psychiatric Disorders
Implications of Access, Effectiveness, and Contextual Treatment
verfasst von
Dr Gloria Reeves
Bruno Anthony
Publikationsdatum
01.06.2009
Verlag
Springer International Publishing
Erschienen in
Pediatric Drugs / Ausgabe 3/2009
Print ISSN: 1174-5878
Elektronische ISSN: 1179-2019
DOI
https://doi.org/10.2165/00148581-200911030-00002

Weitere Artikel der Ausgabe 3/2009

Pediatric Drugs 3/2009 Zur Ausgabe

Adis Drug Evaluation

Atomoxetine

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

23.04.2024 Typ-1-Diabetes Nachrichten

Wenn Kinder an Werktagen zum Arzt gehen, werden neu auftretender Typ-1-Diabetes und diabetische Ketoazidosen häufiger erkannt als bei Arztbesuchen an Wochenenden oder Feiertagen.

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

22.04.2024 Fehlsichtigkeit Nachrichten

Augentropfen mit niedrig dosiertem Atropin können helfen, das Fortschreiten einer Kurzsichtigkeit bei Kindern zumindest zu verlangsamen, wie die Ergebnisse einer aktuellen Studie mit verschiedenen Dosierungen zeigen.

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

18.04.2024 Spinale Muskelatrophien Nachrichten

Seit 2021 ist die Untersuchung auf spinale Muskelatrophie Teil des Neugeborenen-Screenings in Deutschland. Eine Studie liefert weitere Evidenz für den Nutzen der Maßnahme.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.